Chinese drugmakers have signed a late-year burst of out-licensing agreements with overseas partners, underlining China’s growing role as a source of novel medicines as multinational pharma groups hunt for new assets. Jacobio Pharmaceuticals said it expected to receive an upfront payment of US$100 million from AstraZeneca, according to a filing to the Hong Kong stock exchange on December 21. The British-Swedish drugmaker was paying for exclusive rights to research, develop, register, manufacture…
You must log in or # to comment.